⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.
Hepassocin (HPS) as an Age-Declining Hepatokine
Current understanding
Hepassocin (HPS/FGL1) is a liver-secreted hepatokine that declines with age in mice and shows correlative decline in humans; preclinical work positions it as an upstream restraint on hepatocyte senescence and a permissive signal for liver regeneration by activating AMPK through an ANXA2–ERK–p90RSK–LKB1 phosphorylation cascade [animal-model]. Exogenous HPS or the AMPK activator AICAR rescues regeneration and senescence phenotypes in aged mice [animal-model], with only correlative human data so far.
Evidence log
- 2026-09-03 — Aging microenvironment induces CD8T cell exhaustion by suppressing hepatic β-hydroxybutyrylate synthesis.: cross-connection with immunosenescence: Both nominate age-related loss of a hepatic output (BDH1-derived 3HB; hepassocin-driven AMPK tone) as an upstream systemic signal whose decline degrades distal aging phenotypes — a liver-as-aging-hub motif. (novelty: 4)
- 2026-09-15 — Hepassocin prevents age-related liver senescence and facilitates liver regeneration by activating AMPK.: cross-connection with asap3-hepatic-senescence-axis: Both nominate liver-intrinsic upstream nodes gating hepatocyte senescence and healthspan — ASAP3 via actin–autophagy–mitochondria, hepassocin via secreted-factor engagement of LKB1–AMPK. (novelty: 3)
Open questions
Related
Contributing findings
Hepassocin prevents age-related liver senescence and facilitates liver regeneration by activating AMPK.
15-sep-2026
novelty 3
per-area 3
introduces